Genelux (NASDAQ:GNLX) Issues Earnings Results, Misses Estimates By $0.09 EPS

Genelux (NASDAQ:GNLX - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09), Zacks reports.

Genelux Price Performance

GNLX traded down $0.10 on Tuesday, reaching $2.60. The company's stock had a trading volume of 238,823 shares, compared to its average volume of 206,380. Genelux has a 1 year low of $1.60 and a 1 year high of $5.89. The stock has a market cap of $90.29 million, a price-to-earnings ratio of -2.74 and a beta of -1.41. The business's 50 day moving average is $4.06 and its 200 day moving average is $3.10.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Genelux in a report on Monday. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $18.25.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.